Ultragenyx Pharmaceutical Inc.
NASDAQ:RAREBiotechnology
Healthcare
$17.22 +3.01%
+$0.81 today
- Market cap
- $1.76B
- Beta
- 0.38
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$6.06
52W Low $18.29High $42.37
Volume 3.12M
Average 1.81M
Balance Sheet
Inspect the capital base behind the business.
Assets
$1.53B
FY 2025 · Annual
+1.9% YoYLiabilities
$1.60B
FY 2025 · Annual
+29.3% YoYEquity
-$73.00M
FY 2025 · Annual
Balance Sheet
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 307.58M | 132.94M | 213.58M | 173.73M | 434M |
| Short-term Investments | 432.61M | 614.82M | 363.63M | 436.3M | 259M |
| Net Receivables | 44.43M | 40.45M | 73.39M | 121.8M | 159M |
| Inventory | 16.23M | 26.77M | 33.97M | 45.01M | 52M |
| Other Current Assets | 55.75M | 68.93M | 47.62M | 40.29M | 47M |
| Total Current Assets | 856.6M | 883.9M | 732.18M | 817.12M | 951M |
| Property, Plant & Equipment (Net) | 176.18M | 259.73M | 290.57M | 265.93M | 267M |
| Goodwill | 44.41M | 44.41M | 44.41M | 44.41M | 44M |
| Intangible Assets | 130.79M | 160.11M | 166.27M | 178.31M | 176M |
| Long-term Investments | 293.86M | 148.97M | 199.9M | 135M | 59M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 20.56M | 48.34M | 57.69M | 62.68M | 35M |
| Total Non-current Assets | 665.79M | 661.55M | 758.83M | 686.33M | 581M |
| Total Assets | 1.52B | 1.55B | 1.49B | 1.5B | 1.53B |
| Account Payables | 17.14M | 43.27M | 42.11M | 38.76M | 31M |
| Short-term Debt | 0 | 0 | 0 | 0 | 81M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 7.61M | 1.48M | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 142.79M | 87.47M | 183M |
| Total Current Liabilities | 181.37M | 261.21M | 280.44M | 344.15M | 384M |
| Long-term Debt | 0 | 0 | 0 | 0 | 1.17B |
| Deferred Tax Liabilities | 33.31M | 31.67M | 30.06M | 30.06M | 30M |
| Deferred Revenue (Non-current) | 1.47M | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 352.79M | 880.26M | 874.53M | 836.91M | (4M) |
| Total Non-current Liabilities | 418.47M | 931.74M | 935.16M | 897.01M | 1.22B |
| Total Liabilities | 599.84M | 1.19B | 1.22B | 1.24B | 1.61B |
| Common Stock | 69K | 70K | 82K | 92K | 0 |
| Retained Earnings | (2.07B) | (2.78B) | (3.39B) | (3.96B) | (4.53B) |
| Accumulated OCI | (1.4M) | (6.57M) | 647K | (643K) | 1M |
| Other Stockholders Equity | 0 | 0 | 432K | 3.59M | 8M |
| Minority Interest | 0 | 0 | 0 | 7M | 7M |
| Total Equity | 922.56M | 352.49M | 275.41M | 262.3M | (73M) |
| Total Debt | 41.97M | 31.59M | 43.17M | 40.34M | 1.28B |
| Net Debt | (265.61M) | (101.35M) | (170.42M) | (133.39M) | 842M |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $175.0M |
| Short-term Investments | $238.0M |
| Receivables | $121.0M |
| Inventory | $55.0M |
| Other Current | $68.0M |
| Total Current Assets | $657.0M |
| PP&E (Net) | $239.0M |
| Goodwill | $44.0M |
| Intangible Assets | $174.0M |
| Long-term Investments | $127.0M |
| Other Non-current | $55.0M |
| Total Non-current Assets | $639.0M |
| Total Assets | $1.3B |
Analysis
Selected assets total $1.3B for Latest. The largest visible component is PP&E (Net) at $239.0M, about 18.4% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 8-K | Current report | Nov 3, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 30, 2026 |
How much cash does RARE have?
Ultragenyx Pharmaceutical Inc. (RARE) reported $434.00M in cash and equivalents in fiscal 2025.
How much debt does RARE carry?
Ultragenyx Pharmaceutical Inc. (RARE) reported $1.28B of total debt, with net debt of $842.00M.
Continue the stock analysis
Jump to another research area for this company.